This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Oct;3(10):EVIDe2400282.

doi: 10.1056/EVIDe2400282. Epub 2024 Sep 24.

Expanded Access of Unproven Drugs: Not the Final Word

H Clifford Lane¹, Anthony S Fauci²

Affiliations

Affiliations

¹ Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
² School of Medicine and the McCourt School of Public Policy, Georgetown University, Washington, DC.

PMID: 39315872
DOI: 10.1056/EVIDe2400282

Editorial

Expanded Access of Unproven Drugs: Not the Final Word

H Clifford Lane et al. NEJM Evid. 2024 Oct.

. 2024 Oct;3(10):EVIDe2400282.

doi: 10.1056/EVIDe2400282. Epub 2024 Sep 24.

Authors

H Clifford Lane¹, Anthony S Fauci²

Affiliations

¹ Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
² School of Medicine and the McCourt School of Public Policy, Georgetown University, Washington, DC.

PMID: 39315872
DOI: 10.1056/EVIDe2400282

No abstract available

PubMed Disclaimer

Comment on

Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023.
Yu PA, Elmor R, Muhammad K, Yu YC, Rao AK. Yu PA, et al. NEJM Evid. 2024 Oct;3(10):EVIDoa2400189. doi: 10.1056/EVIDoa2400189. Epub 2024 Sep 13. NEJM Evid. 2024. PMID: 39270215 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.